Dr. Beaudry is the holder of a Canada Research Chair in metrology of bioactive molecule and target discovery. Dr. Beaudry lab aims to methodically characterize the molecular signature of animal models employed to study diseases, identify new bioactive molecules and their targets to design innovative therapeutic strategies and improve the translation of drugs to the clinic. One major objective is to predict how a drug will behave in humans before clinical testing. A good drug candidate needs to possess adequate bioactivity, appropriate physical–chemical properties, sufficient metabolic stability and suitable safety and efficacy. Dr. Beaudry lab develop and use state-of-the-art mass spectrometry analytical strategies to perform proteomics and analysis of xenobiotics. Moreover, his team utilizes cutting-edge bioinformatics and data modeling to generate vast amounts of information and data to gather more knowledge about the characteristics of a drug to improve translation to the clinic.